Condition: Relapsed/Refractory Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS) · Sponsor: Cullinan Therapeutics Inc.
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This description comes directly from the study's public registry record.
Timna Serino · +1 617 410 4650 · ClinOps@cullinantx.com
Always discuss trial participation with your own doctor first.
| University of Alabama O'Neal Cancer Center | Birmingham, Alabama, United States | Recruiting |
| UCLA | Los Angeles, California, United States | Recruiting |
| University of Miami Health System | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Completed |
| Roswell Park Cancer Institute | Buffalo, New York, United States | Recruiting |
| New York University | New York, New York, United States | Recruiting |
| Duke Cancer Center | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Withdrawn |
| MD Anderson | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05143996